Communiqués Grifols, S.A.

Actions

GRF

ES0171996087

Produits pharmaceutiques

Marché Fermé - BME Autres places de cotation 17:35:28 21/07/2026			Après clôture 18:58:37
9,570 ^EUR	+1,64%		9,591	+0,22%

20/07	Les actions européennes cotées aux États-Unis sous forme d'ADR s'inscrivent en baisse lors de la séance de lundi	MT
16/07	Les bourses européennes terminent majoritairement en baisse jeudi ; Sodexo retenu par Meta pour ses services de restauration mondiaux	MT

Communiqués

16/07	Grifols S A : doses first patients in two Phase 3 trials to expand indications of its flagship immunoglobulins	PU
01/07	Grifols S A : reorganizes its operating model to accelerate execution of its strategic roadmap	PU
29/06	Grifols S A : doses first participant in Phase 3 study evaluating novel subcutaneous therapy for alpha1-antitrypsin deficiency	PU
26/06	Delisting (ISIN NUMBER: XS2077646391 (Reg. S) / XS2077647365 (144A))	AQ
26/06	Partial Redemption (ISIN NUMBER: XS2805351843 (Reg. S) / XS2805352064 (144A))	AQ
22/06	Changes in the Composition of the Board of Directors and Board Committees	AQ
18/06	Grifols S A : Shareholders approve key resolutions at the 2026 Annual General Shareholders’ Meeting	PU
18/06	Grifols Communications - Resolutions adopted by the Board of Directors	AQ
15/06	Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S.	AQ
12/06	Grifols S A : Egypt continues its growth plan through 2029 with an additional investment of €180 million	PU
03/06	Grifols S A : breaks ground on new manufacturing site in Spain	PU
26/05	Grifols S A : doubles the number of positions in its vocational training program over the past year in Spain	PU
15/05	Ordinary General Shareholders' Meeting	AQ
08/05	Grifols S A : Conference call transcript (a065ff21 61b9 2f2c 67fc 1284cdbb08dct1778229612320)	PU
07/05	Grifols S A : ’ Alternative Performance Measures (a9fc8d43 cea3 1a96 9cf3 2378f1b7cf0dt1778167399199)	PU
07/05	Grifols Q1 2026 Financial Results	AQ
04/05	Grifols S A : strengthens its position among the world’s most sustainable biotechnology companies after improving its Dow Jones Best-in-Class score	PU
04/05	Grifols S A : strengthens its position among the world’s most sustainable biotechnology companies after improving its Dow Jones Best-in-Class score May 4 2026	PU
24/04	Grifols S A : streamlines its global plasma network with the closure of 29 donation centers in the U.S.	PU
24/04	Grifols S A : streamlines its global plasma network with the closure of 29 donation centers in the U.S. April 24 2026	PU
17/04	Grifols S A : GigaGen presents positive phase 1 data on non-blocking anti-CTLA-4 drug candidate GIGA-564 at AACR 2026	PU
16/04	Grifols S A : receives FDA approval for its malaria blood screening assay	PU
14/04	Grifols S A : successfully completes refinancing of 2027 maturities, further strengthening balance sheet and extending debt profile	PU
14/04	Grifols S A : successfully completes refinancing of 2027 maturities, further strengthening balance sheet and extending debt profile April 14 2026	PU
14/04	Grifols has concluded today a successful refinancing of its 2027 debt maturities	AQ